



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,529	07/07/2005	Bernd Fabry	C 2776 PCT/US	1490
23657	7590	10/05/2007	EXAMINER	
COGNIS CORPORATION			CHEN, CATHERYNE	
PATENT DEPARTMENT			ART UNIT	PAPER NUMBER
300 BROOKSIDE AVENUE			1655	
AMBLER, PA 19002				

  

MAIL DATE	DELIVERY MODE
10/05/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/541,529	FABRY, BERND	
	<b>Examiner</b>	<b>Art Unit</b>	
	Catheryne Chen	1655	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 13 July 2007.
- 2a) This action is **FINAL**.                                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 11-29 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 11-29 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____	6) <input type="checkbox"/> Other: _____

### **DETAILED ACTION**

The Amendments filed on July 13, 2007 has been received and entered.

Currently, Claims 11-29 are pending. Claims 1-10 are canceled.

#### ***Election/Restrictions***

Applicant's election with traverse of Claims 11-29 in the reply filed on Dec. 22, 2006 is acknowledged. Applicant elects the species Trifolium pretense and isoflavone glucosides. Claims 1-10 are canceled. Claims 11-29 are amended claims.

#### ***Response to Arguments***

Applicant's arguments with respect to claims 12-29 have been considered but are moot in view of the new ground(s) of rejection.

#### ***Claim Objections***

Claim 11 is objected to because of the following informalities: "Olea euorpensis" is misspelled. Appropriate correction is required.

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 11-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Empie et al. (US 6261565 B1), Hernandez (US 635435 B1), and Gurin (US 2002/0160077 A1).

Empie et al. teaches red clover (*Trifolium pretense*) (column 4, line 19), orally administered as soft gels (column 7, lines 25, 31). However, it does not teach *Olea europea*, and the other components or amounts.

Hernandez teaches olive oil (*Olea europea L.*) in chewing gum (Abstract).

Gurin teaches chewing gum (paragraph 0004), gum components from elastomers, plasticizers, fillers, softeners, waxes, antioxidants, colorants, emulsifiers, colos, acidulents, flavors, and colors (paragraph 0008), a water soluble gum portion and a water insoluble gum base portion (paragraph 0030), chitosan, polylactic polymers (paragraph 0052), proportion of water soluble component to oil soluble component distributed throughout the oil phase, causes the phases to become encapsulated, or by emulsifying the two phases by means of an emulsifying agent (paragraph 0044), cellulose fibers having particle size of not greater than 400 microns (paragraph 0069).

Art Unit: 1655

The references also do not specifically teach combining all of the claimed components together. The references do teach that *Trifolium pratense* is orally administered as soft gels (see Empie et al., column 7, lines 25, 31), which includes chewing gum. As discussed in MPEP 2144.06:

It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.

Thus, it would be obvious to combine the claimed ingredients with components to make a chewing gum for oral administration because they are taught in the reference to have the same purpose.

The references also do not specifically teach adding the ingredients in the amounts claimed by applicant. The amount of a specific ingredient in a composition is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Thus, optimization of general conditions is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each ingredient to add in order to best achieve the desired results. Thus, absent some demonstration of

Art Unit: 1655

unexpected results from the claimed parameters, this optimization of ingredient amount would have been obvious at the time of applicant's invention.

Claims 11-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over He et al. (US 6413546 B1), Hernandez (US 635435 B1), and Gurin (US 2002/0160077 A1).

He et al. teaches disintegratable tablets containing isoflavone from red clover and soybean (column 1, lines 36-37; column 2, lines 5-7), isoflavone glucosides (column 7, line 34). However, it does not teach the other components or amounts.

Hernandez teaches olive oil (*Olea europea L.*) in chewing gum (Abstract).

Gurin teaches chewing gum (paragraph 0004), gum components from elastomers, plasticizers, fillers, softeners, waxes, antioxidants, colorants, emulsifiers, colos, acidulents, flavors, and colors (paragraph 0008), a water soluble gum portion and a water insoluble gum base portion (paragraph 0030), chitosan, polylactic polymers (paragraph 0052), proportion of water soluble component to oil soluble component distributed throughout the oil phase, causes the phases to become encapsulated, or by emulsifying the two phases by means of an emulsifying agent (paragraph 0044), cellulose fibers having particle size of not greater than 400 microns (paragraph 0069).

The references also do not specifically teach combining *Trifolium pratense* and the claimed components together. The references do teach that *Trifolium pratense* is orally administered as tablets (see He et al., column 1, lines 36-37). As discussed in MPEP 2144.06:

It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be

used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.

Thus, it would be obvious to combine *Trifolium pratense* with components to make a chewing gum for oral administration because they are taught in the reference to have the same purpose.

The references also do not specifically teach adding the ingredients in the amounts claimed by applicant. The amount of a specific ingredient in a composition is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Thus, optimization of general conditions is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each ingredient to add in order to best achieve the desired results. Thus, absent some demonstration of unexpected results from the claimed parameters, this optimization of ingredient amount would have been obvious at the time of applicant's invention.

### ***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catheryne Chen whose telephone number is 571-272-9947. The examiner can normally be reached on Monday to Friday, 9-5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1655

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Catheryne Chen  
Patent Examiner  
Art Unit 1655

/Susan Hoffman/  
Primary Examiner, Art Unit 1655  
September 25, 2007